CA2260855C - Polynucleotide vaccine formula in particular against bovine respiratory pathology - Google Patents
Polynucleotide vaccine formula in particular against bovine respiratory pathology Download PDFInfo
- Publication number
- CA2260855C CA2260855C CA2260855A CA2260855A CA2260855C CA 2260855 C CA2260855 C CA 2260855C CA 2260855 A CA2260855 A CA 2260855A CA 2260855 A CA2260855 A CA 2260855A CA 2260855 C CA2260855 C CA 2260855C
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- plasmid
- protein
- virus
- bovine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 44
- 230000000241 respiratory effect Effects 0.000 title claims description 12
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title abstract description 10
- 230000007170 pathology Effects 0.000 title description 13
- 229960005486 vaccine Drugs 0.000 claims abstract description 97
- 239000013612 plasmid Substances 0.000 claims abstract description 94
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 241000711895 Bovine orthopneumovirus Species 0.000 claims abstract description 23
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 14
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 37
- 238000002255 vaccination Methods 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 12
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108091006027 G proteins Proteins 0.000 claims description 6
- 102000030782 GTP binding Human genes 0.000 claims description 6
- 108091000058 GTP-Binding Proteins 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 229940031626 subunit vaccine Drugs 0.000 claims description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims description 5
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 5
- 229940124551 recombinant vaccine Drugs 0.000 claims description 5
- 210000004292 cytoskeleton Anatomy 0.000 claims description 3
- 102000007469 Actins Human genes 0.000 claims description 2
- 108010085238 Actins Proteins 0.000 claims description 2
- 102100036912 Desmin Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 2
- 241000714474 Rous sarcoma virus Species 0.000 claims description 2
- 210000005045 desmin Anatomy 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 abstract description 4
- 208000023504 respiratory system disease Diseases 0.000 abstract description 4
- 241000712003 Human respirovirus 3 Species 0.000 abstract 2
- 239000012634 fragment Substances 0.000 description 44
- 238000000034 method Methods 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 241000700585 Bovine alphaherpesvirus 2 Species 0.000 description 19
- 238000010276 construction Methods 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101150034814 F gene Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101150008820 HN gene Proteins 0.000 description 3
- 206010051511 Viral diarrhoea Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229940031346 monovalent vaccine Drugs 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 241000712005 Bovine respirovirus 3 Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 101150029683 gB gene Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/813—Viral vaccine for bovine species, e.g. cattle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9609403A FR2751229B1 (fr) | 1996-07-19 | 1996-07-19 | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| FR9609403 | 1996-07-19 | ||
| PCT/FR1997/001325 WO1998003200A2 (fr) | 1996-07-19 | 1997-07-16 | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2260855A1 CA2260855A1 (en) | 1998-01-29 |
| CA2260855C true CA2260855C (en) | 2012-01-03 |
Family
ID=9494497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2260855A Expired - Lifetime CA2260855C (en) | 1996-07-19 | 1997-07-16 | Polynucleotide vaccine formula in particular against bovine respiratory pathology |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6376473B1 (OSRAM) |
| EP (2) | EP1382348B1 (OSRAM) |
| JP (1) | JP2000516200A (OSRAM) |
| AP (1) | AP9701044A0 (OSRAM) |
| AR (1) | AR007862A1 (OSRAM) |
| AT (2) | ATE307607T1 (OSRAM) |
| AU (1) | AU734442B2 (OSRAM) |
| BR (1) | BR9710506A (OSRAM) |
| CA (1) | CA2260855C (OSRAM) |
| CO (1) | CO4700306A1 (OSRAM) |
| CZ (2) | CZ298898B6 (OSRAM) |
| DE (2) | DE69725988T2 (OSRAM) |
| DK (2) | DK1382348T3 (OSRAM) |
| ES (2) | ES2254833T3 (OSRAM) |
| FR (1) | FR2751229B1 (OSRAM) |
| HR (1) | HRP970383A2 (OSRAM) |
| HU (2) | HU225169B1 (OSRAM) |
| ID (1) | ID19513A (OSRAM) |
| IL (2) | IL127703A0 (OSRAM) |
| MA (1) | MA24269A1 (OSRAM) |
| NZ (4) | NZ508939A (OSRAM) |
| PE (1) | PE84699A1 (OSRAM) |
| PL (1) | PL190122B1 (OSRAM) |
| PT (1) | PT912194E (OSRAM) |
| RU (1) | RU2305560C2 (OSRAM) |
| UA (1) | UA70914C2 (OSRAM) |
| WO (1) | WO1998003200A2 (OSRAM) |
| ZA (1) | ZA976283B (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751229B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| US20040002472A1 (en) * | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
| US6852705B2 (en) * | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
| US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
| EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| WO2005049794A2 (en) | 2003-11-13 | 2005-06-02 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
| EP1718770B1 (en) | 2004-02-19 | 2011-05-25 | The Governors of the University of Alberta | Leptin promoter polymorphisms and uses thereof |
| RS51324B (sr) | 2005-04-25 | 2010-12-31 | Merial Ltd. | Vakcine protiv nipah virusa |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP3147296A1 (en) | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
| BRPI0721630A2 (pt) | 2007-05-02 | 2013-10-15 | Merial Ltd | Plasmídeo de dna tendo expressão e estabilidade aperfeiçoadas |
| US8394384B2 (en) | 2008-11-28 | 2013-03-12 | Merial Limited | Recombinant avian influenza vaccine and uses thereof |
| MX347997B (es) | 2009-04-03 | 2017-05-22 | Merial Ltd | Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle. |
| WO2011090708A2 (en) | 2009-12-28 | 2011-07-28 | Merial Limited | Recombinant ndv antigen and uses thereof |
| ES2678143T3 (es) | 2010-01-19 | 2018-08-09 | President And Fellows Of Harvard College | Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| MA34087B1 (fr) | 2010-03-12 | 2013-03-05 | Merial Ltd | Vaccins recombinants contre le virus de la langue bleue et leurs utilisations |
| PL2611460T3 (pl) | 2010-08-31 | 2017-02-28 | Merial, Inc. | Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle |
| AR084358A1 (es) * | 2010-12-27 | 2013-05-08 | Lilly Co Eli | Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc)) |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| CN103945864A (zh) | 2011-04-25 | 2014-07-23 | 先进生物学实验室股份有限公司 | 截短的hiv包膜蛋白(env)、其相关方法和组合物 |
| EP2714722B1 (en) | 2011-05-27 | 2019-09-11 | Boehringer Ingelheim Animal Health USA Inc. | Genetic vaccines against hendra virus and nipah virus |
| ES2674439T3 (es) | 2011-06-01 | 2018-06-29 | Merial, Inc. | Administración sin aguja de vacunas contra el VSRRP |
| SG10201608671SA (en) | 2011-07-18 | 2016-12-29 | Harvard College | Engineered Microbe-Targeting Molecules and Uses Thereof |
| WO2013025274A1 (en) | 2011-08-12 | 2013-02-21 | Merial Limited | Vacuum -assisted preservation of biological products, in particular of vaccines |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| US20130177591A1 (en) | 2012-01-10 | 2013-07-11 | Merial Limited | Lipid Based Adjuvants for DNA Plasmids |
| WO2013123242A1 (en) | 2012-02-14 | 2013-08-22 | Merial Limited | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
| EP2814508B1 (en) | 2012-02-14 | 2017-04-12 | Merial, Inc. | Rotavirus subunit vaccines and methods of making and use thereof |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| ES2664069T3 (es) | 2012-06-13 | 2018-04-18 | Merial, Inc. | Vacunas contra BTV y AHSV de genoma reordenado |
| CN109266622B (zh) | 2012-08-01 | 2023-05-09 | 巴法里安诺迪克有限公司 | 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗 |
| WO2014164697A1 (en) | 2013-03-12 | 2014-10-09 | Merial Limited | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
| US10551379B2 (en) | 2013-03-15 | 2020-02-04 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
| JP6649250B2 (ja) | 2013-05-21 | 2020-02-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたヘム結合性構成物およびその使用 |
| EP3083658B1 (en) | 2013-12-18 | 2019-05-08 | President and Fellows of Harvard College | Crp capture/detection of gram positive bacteria |
| AU2015343369B2 (en) | 2014-11-03 | 2018-11-22 | Georgia Tech Research Corporation | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| ES3050936T3 (en) | 2015-06-23 | 2025-12-23 | Boehringer Ingelheim Vetmedica Gmbh | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
| EP3331549B1 (en) | 2015-08-06 | 2020-12-23 | President and Fellows of Harvard College | Improved microbe-binding molecules and uses thereof |
| NZ740551A (en) | 2015-08-20 | 2019-10-25 | Boehringer Ingelheim Animal Health Usa Inc | Fcv recombinant vaccines and uses thereof |
| RS65084B1 (sr) | 2015-09-29 | 2024-02-29 | Boehringer Ingelheim Animal Health Usa Inc | Vakcine čestica sličnih virusu (vlp) parvovirusa pasa (cpv) i njihova upotreba |
| EP3380119B1 (en) | 2015-11-23 | 2021-08-25 | Boehringer Ingelheim Animal Health USA Inc. | Fmdv and e2 fusion proteins and uses thereof |
| TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
| CN109021081B (zh) * | 2018-08-10 | 2019-06-04 | 山东大学 | 一种牛病毒性腹泻病毒样颗粒及其构建方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989010405A1 (en) * | 1988-04-22 | 1989-11-02 | The Upjohn Company | Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3 |
| NZ239084A (en) * | 1990-07-24 | 1994-09-27 | Uab Research Foundation | Bovine respiratory virus (brs) f glycoprotein and vaccine therefrom |
| GB9200117D0 (en) * | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
| CA2136677A1 (en) * | 1993-12-29 | 1995-06-30 | Intervet, Inc. | Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv |
| ATE475668T1 (de) * | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| US5541102A (en) * | 1994-09-02 | 1996-07-30 | Board Of Regents, University Of Nebraska-Lincoln | Bovine cell line resistant to in vitro infection by bovine viral diarrhea virus and all other known pestiviruses |
| US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6060457A (en) | 1996-06-20 | 2000-05-09 | Universite De Montreal | DNA plasmid vaccine for immunization of animals against BVDV |
| FR2751229B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| JP5566663B2 (ja) * | 2009-11-09 | 2014-08-06 | 三菱重工業株式会社 | 多翼遠心ファンおよびそれを用いた空気調和機 |
-
1996
- 1996-07-19 FR FR9609403A patent/FR2751229B1/fr not_active Expired - Lifetime
-
1997
- 1997-07-06 NZ NZ508939A patent/NZ508939A/en not_active IP Right Cessation
- 1997-07-06 NZ NZ508940A patent/NZ508940A/xx not_active IP Right Cessation
- 1997-07-06 NZ NZ517686A patent/NZ517686A/xx not_active IP Right Cessation
- 1997-07-11 AR ARP970103111A patent/AR007862A1/es active IP Right Grant
- 1997-07-15 HR HR9609403A patent/HRP970383A2/hr not_active Application Discontinuation
- 1997-07-16 EP EP03016996A patent/EP1382348B1/fr not_active Expired - Lifetime
- 1997-07-16 CZ CZ0017599A patent/CZ298898B6/cs not_active IP Right Cessation
- 1997-07-16 EP EP97934578A patent/EP0912194B1/fr not_active Expired - Lifetime
- 1997-07-16 PT PT97934578T patent/PT912194E/pt unknown
- 1997-07-16 DE DE69725988T patent/DE69725988T2/de not_active Expired - Lifetime
- 1997-07-16 AT AT03016996T patent/ATE307607T1/de active
- 1997-07-16 CZ CZ20070776A patent/CZ298915B6/cs not_active IP Right Cessation
- 1997-07-16 ES ES03016996T patent/ES2254833T3/es not_active Expired - Lifetime
- 1997-07-16 AU AU37735/97A patent/AU734442B2/en not_active Expired
- 1997-07-16 ES ES97934578T patent/ES2210548T3/es not_active Expired - Lifetime
- 1997-07-16 AT AT97934578T patent/ATE253376T1/de active
- 1997-07-16 ZA ZA976283A patent/ZA976283B/xx unknown
- 1997-07-16 WO PCT/FR1997/001325 patent/WO1998003200A2/fr not_active Ceased
- 1997-07-16 ID IDP972480A patent/ID19513A/id unknown
- 1997-07-16 DE DE69734483T patent/DE69734483T2/de not_active Expired - Lifetime
- 1997-07-16 IL IL12770397A patent/IL127703A0/xx active IP Right Grant
- 1997-07-16 UA UA99020960A patent/UA70914C2/uk unknown
- 1997-07-16 PL PL97331236A patent/PL190122B1/pl unknown
- 1997-07-16 HU HU9902791A patent/HU225169B1/hu unknown
- 1997-07-16 DK DK03016996T patent/DK1382348T3/da active
- 1997-07-16 HU HU0500910A patent/HU228353B1/hu unknown
- 1997-07-16 NZ NZ333751A patent/NZ333751A/en not_active IP Right Cessation
- 1997-07-16 DK DK97934578T patent/DK0912194T3/da active
- 1997-07-16 BR BR9710506A patent/BR9710506A/pt not_active Application Discontinuation
- 1997-07-16 JP JP09535655A patent/JP2000516200A/ja active Pending
- 1997-07-16 MA MA24716A patent/MA24269A1/fr unknown
- 1997-07-16 CA CA2260855A patent/CA2260855C/en not_active Expired - Lifetime
- 1997-07-17 AP APAP/P/1997/001044A patent/AP9701044A0/en unknown
- 1997-07-18 CO CO97040983A patent/CO4700306A1/es unknown
-
1998
- 1998-01-16 PE PE1998000035A patent/PE84699A1/es not_active Application Discontinuation
- 1998-12-23 IL IL127703A patent/IL127703A/en not_active IP Right Cessation
-
1999
- 1999-01-15 US US09/232,279 patent/US6376473B1/en not_active Expired - Lifetime
-
2002
- 2002-02-28 US US10/085,519 patent/US6818628B2/en not_active Expired - Lifetime
- 2002-12-05 RU RU2002132831/13A patent/RU2305560C2/ru active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2260855C (en) | Polynucleotide vaccine formula in particular against bovine respiratory pathology | |
| CA2260273C (en) | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies | |
| US7534559B2 (en) | Feline polynucleotide vaccine formula | |
| CA2260858C (en) | Polynucleotide vaccine formulation against pathologies of the horse | |
| CN1329513C (zh) | 抗猪生殖和呼吸疾病的多核苷酸疫苗制剂 | |
| AU2844899A (en) | Adjuvant-containing vaccines | |
| AU776827B2 (en) | Polynucleotide vaccine formula, particularly for treating bovine respiratory disease | |
| US7294338B2 (en) | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies | |
| AU2004205140B2 (en) | Feline polynucleotide vaccine formula | |
| AU773266B2 (en) | Feline polynucleotide vaccine formula | |
| NZ506427A (en) | A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter | |
| AU2008203549A1 (en) | Feline polynucleotide vaccine formula | |
| AU5427401A (en) | Polynucleotide vaccine formula for treating horse diseases | |
| AU2007202367A1 (en) | Avian polynucleotide vaccine formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20170717 |